Thymosin Alpha-1

Compound background

Thymosin α-1 is a 28-amino-acid thymic peptide that serves as an immune modulator: by binding Toll-like receptors 2 and 9 on dendritic and other innate immune cells, it enhances antigen presentation, expands CD4⁺/CD8⁺ T- and NK-cell activity, elevates interferon-γ and IL-12 while damping excess TNF-α and IL-1β, and up-regulates MHC-I expression—sharpening antiviral and antitumor defenses without provoking cytokine storm. Clinically licensed in many countries to support treatment of chronic hepatitis B/C and to bolster vaccine responses in immunocompromised hosts, it is now being investigated as an adjunct to checkpoint inhibitors in cancer, as a lymphocyte-restoring therapy in severe viral infections (e.g., COVID-19), and as a sepsis modulator, where benefits appear to depend on timing and patient selection. Overall, accumulated evidence depicts thymosin α-1 as a homeostatic “immune re-balancer” that nudges innate sensors so adaptive immunity can self-correct, offering broad therapeutic potential with a favorable safety profile.

Quality standards

• Greater than 99% pure
• Endotoxin-free
• Sterility guaranteed
• No detectable levels of heavy metals

Sourcing standards

• Raw ingredients manufactured by an FDA registered & audited supplier following cGMP standards
• Finished peptides 0.22 µm sterile-filtered (aseptically processed) & produced in a GMP facility
• Tested by a US FDA registered & audited third-party analytical lab accredited by ISO/IEC and U.S. Department of Ecology

Analytical reports

Batch 1356 – Thymosin Alpha 1 99.41 11.86mg